The aging of the global population is one of the defining challenges of twenty-first century medicine. By 2050, the number of people aged 60 and older is projected to surpass 2 billion — nearly double the current figure. Against that backdrop, the science of aging has never been more productive. Researchers are unraveling the molecular drivers of longevity, mapping risk factors for age-related disease, and testing interventions that can add healthy years to lives in ways that were unimaginable a generation ago.
Yet progress in the laboratory is only meaningful if it reaches the patient. And in gerontology, that journey is rarely straightforward.
There is a well-documented lag — sometimes stretching to 17 years — between a research breakthrough and its routine use in clinical care. In a field where the patients are among the most medically complex, and where the cost of outdated practice is measured in preventable disability and avoidable decline, that lag is not an abstract problem. It is a public health failure that demands active intervention.
This is where the International Association of Gerontology and Geriatrics (IAGG) plays a role that no other organization quite replicates. As the world’s preeminent global body in aging science, IAGG operates at the intersection of discovery and delivery — working systematically to ensure that the best available evidence in gerontology research reaches the clinicians, care systems, educators, and policymakers who shape the health of older adults worldwide.
This article examines how IAGG does that work: the mechanisms it uses, the priority areas it targets, and the structural partnerships it has built to close the gap between the research bench and the clinical bedside.
Why the Translation Gap Is Especially Consequential in Gerontology
The problem of slow research translation is not unique to aging science — it affects medicine broadly. But several features of gerontology make the gap especially acute and the stakes especially high.
- Older adults are underrepresented in clinical trials. For decades, patients over 75 — particularly those with multiple chronic conditions — have been systematically excluded from the trials that generate clinical evidence. This means that a substantial portion of prescribing, dosing, and treatment decisions for older patients rests on data collected largely from younger populations.
- Aging is biologically heterogeneous. Two 80-year-olds can differ from each other far more than two 40-year-olds. Applying population-level evidence to individual older patients requires clinical judgment that itself depends on up-to-date training and knowledge.
- Multi-morbidity complicates implementation. Most older adults live with two or more chronic conditions. Clinical guidelines designed for single diseases rarely provide clear direction when multiple conditions — and their respective treatment regimens — interact.
- Care systems are often fragmented. Integrated, evidence-based geriatric care depends on teams working across disciplines. Many health systems are not structured to deliver that kind of care consistently or at scale.
These barriers mean that even rigorously validated advances — in areas like frailty identification, polypharmacy reduction, or cognitive screening — can take years to reshape routine clinical practice. Addressing them requires organized, sustained effort at both the scientific and systems level.
IAGG as a Bridge Between Discovery and Clinical Care
Founded in 1950, the International Association of Gerontology and Geriatrics has spent more than seven decades fostering collaboration among scientists, clinicians, and policymakers across more than 70 countries. Its membership encompasses the full spectrum of aging science — from fundamental biology and neuroscience to geriatric medicine, nursing, social gerontology, rehabilitation, and public health.
That breadth is not incidental; it is the foundation of IAGG’s translational capacity. Moving knowledge from a research paper into a clinical protocol requires the full ecosystem of people and institutions involved in aging: those who generate evidence, those who synthesize it, those who apply it at the bedside, and those who train the next generation to do so. International Association of Gerontology and Geriatrics IAGG brings all of these actors into sustained dialogue in a way that single-discipline societies cannot.
A Global Network With Local Reach
IAGG is structured through five regional associations spanning Africa, Asia/Oceania, Europe, Latin America, and North America. This architecture is strategically important for translation. A clinical recommendation shaped by researchers and clinicians from multiple continents is more likely to be contextually relevant — and practically adoptable — across diverse health systems than guidance developed in a single academic setting.
Regional connectivity also helps identify precisely where translation is failing: where evidence-based practices exist but are not being implemented, and what the barriers are. Those barriers differ significantly between a rural clinic in sub-Saharan Africa and a university hospital in Western Europe. Understanding them at that level of specificity is the prerequisite for addressing them.
Key Mechanisms for Moving Research Into Practice
The International Association of Gerontology and Geriatrics employs a deliberate set of mechanisms to accelerate the movement of evidence from research into clinical and policy settings. These are not passive information-sharing activities — they are structured efforts to generate consensus, communicate findings to the right audiences, and embed evidence into the tools and workflows that clinicians actually use.
World Congresses and Scientific Meetings
The IAGG World Congress, held every four years, is the largest global gathering in the field of aging science. Beyond its scale, what distinguishes the Congress is its explicit design for translational exchange. Pre-congress workshops, clinical symposia, and case-based sessions are structured to bring researchers and clinicians into direct dialogue — to challenge findings, expose implementation difficulties, and begin building the clinical consensus that precedes uptake. Between World Congresses, IAGG’s regional associations maintain their own active scientific meeting programs, ensuring that translational conversations continue year-round across all regions.
Task Forces and Expert Working Groups
Among IAGG’s most direct translational tools are its task forces and expert working groups. These bodies convene specialists from multiple disciplines to review current evidence, identify gaps between research findings and clinical practice, and produce consensus recommendations that clinicians can act on. Critically, task forces engage not only with the academic community but with clinical professional societies, national health ministries, and international bodies such as the World Health Organization — ensuring that recommendations carry weight beyond the gerontology field itself.
Publications and Knowledge Dissemination
IAGG supports a portfolio of peer-reviewed journals — including Gerontology and the Journal of Nutrition, Health & Aging — that prioritize clinical relevance alongside scientific rigor. An increasing emphasis on open-access publishing, systematic reviews, and plain-language summaries means that high-quality findings reach not only academic researchers but frontline practitioners who do not have the time or institutional access to navigate specialized literature independently.
Summary of Key Translational Mechanisms
| Mechanism | Primary Purpose | Principal Audiences |
|---|---|---|
| World Congresses | Consensus building and global dissemination | Researchers, clinicians, policymakers |
| Task Forces and Working Groups | Evidence synthesis and clinical recommendations | Clinicians, health systems |
| Peer-Reviewed Journals | Rigorous scientific publication | Academic and clinical communities |
| Regional Association Events | Contextualizing evidence for local practice | Regional and national practitioners |
| WHO and UN Partnerships | Policy influence and global advocacy | Governments, international bodies |
| Education and Training Initiatives | Workforce development and competency standards | Students, clinicians, caregivers |
Priority Clinical Areas: Where Translation Is Making a Difference
IAGG’s translational work is concentrated in areas where the evidence base is strong and the need for clinical application is greatest. Several of these areas illustrate what sustained, organized translation effort can achieve.
Frailty: From Research Concept to Clinical Tool
Frailty — broadly defined as a state of reduced physiological reserve that increases vulnerability to adverse health outcomes following minor stressors — was, until relatively recently, primarily a research construct. It was discussed in journals and conference halls but had little presence in clinical decision-making. Through sustained effort by IAGG-affiliated researchers and task forces, frailty has been operationalized into validated, practical assessment instruments: the Clinical Frailty Scale, the Fried Frailty Phenotype, and others that are now embedded in pre-operative assessments, hospital admission protocols, and outpatient geriatric evaluations worldwide. That transformation — from concept to bedside tool — did not happen automatically. It required the kind of sustained consensus-building and dissemination effort that IAGG is structured to provide.
Sarcopenia: Achieving Clinical Recognition
Age-related muscle loss — sarcopenia — spent decades in a scientific limbo: widely researched but lacking a universally accepted clinical definition, which made it nearly impossible to diagnose, code, or treat consistently in practice. The European Working Group on Sarcopenia in Older People (EWGSOP), operating under IAGG’s European regional structure, produced a landmark consensus definition that resolved that impasse. It has since been adopted across multiple clinical specialties and is now recognized by the World Health Organization as a disease entity. This is among the clearest examples in modern gerontology of what structured, internationally coordinated translation effort can accomplish.
Cognitive Aging and Dementia Prevention
IAGG’s engagement with cognitive aging spans multiple decades and continues to intensify as the global dementia burden grows. Working groups have focused on distinguishing normal cognitive aging from pathological decline, identifying modifiable risk factors — including cardiovascular risk, social isolation, hearing loss, and physical inactivity — and integrating evidence-based cognitive screening into routine geriatric assessment. With dementia prevalence projected to triple globally by 2050, IAGG’s work synthesizing and communicating research in this domain carries exceptional public health weight.
Falls Prevention
Falls remain the leading cause of injury-related death among older adults globally. Importantly, they are also substantially preventable. IAGG has supported the translation of multi-factorial falls prevention evidence into structured clinical protocols, working in concert with national health authorities to embed fall risk assessment into standard care pathways. The evidence on interventions — from exercise programs and medication review to home modification and vision correction — has been available for years. The challenge has been implementation, and IAGG has been consistently active in addressing it.
Building the Clinical Workforce That Delivers Evidence-Based Care
Research translation is ultimately a human capacity problem as much as an information problem. Evidence that exists but is unknown to frontline clinicians — or known but not yet embedded in their clinical reasoning — cannot improve patient outcomes. The International Association of Gerontology and Geriatrics recognizes that building a workforce capable of applying current evidence is as important as generating it.
Shaping Educational Standards
IAGG collaborates with medical schools, nursing institutions, and professional development bodies globally to influence gerontology and geriatrics curricula. By helping establish core clinical competencies and supporting the development of teaching resources, IAGG works to ensure that healthcare professionals enter practice already equipped to deliver evidence-based care to older patients — rather than spending years catching up with a field that has advanced since their training.
Addressing the Equity Gap in Low- and Middle-Income Countries
One of the most troubling dimensions of the translation gap is how unevenly it is distributed. In high-income countries, slow uptake is the primary problem; in low- and middle-income countries, the gap is often compounded by limited access to current literature, under-resourced health systems, and a shortage of trained geriatric specialists. IAGG addresses this directly through targeted educational programs, capacity-building partnerships, and advocacy for equitable access to evidence-based geriatric practice. Crucially, the objective is not to transplant high-income country models wholesale, but to support locally driven clinical practice that is grounded in sound evidence and adapted to local realities.
Collaboration With Global Health Bodies and Policy Institutions
The International Association of Gerontology and Geriatrics maintains formal relationships with the World Health Organization, the United Nations, and an extensive network of national and international clinical societies. These partnerships are essential because translating research into practice is not only a scientific challenge — it is a systems challenge. Clinical protocols, health financing, regulatory frameworks, and workforce policy all shape whether evidence-based care actually reaches patients. IAGG’s influence at the policy level amplifies its scientific work in ways that no amount of publication alone could achieve.
IAGG is an active participant in the UN Decade of Healthy Ageing (2021–2030), a global initiative that aligns governments, civil society, international agencies, and academic institutions around improving the lives of older people. For IAGG, participation in this framework is not symbolic — it is a concrete opportunity to align translational priorities with binding international commitments, and to hold health systems accountable for closing the gap between what the evidence supports and what older patients receive.
Conclusion: Closing the Gap Is an Ongoing Commitment
The gap between a research finding and a patient who benefits from it is not inevitable. It exists because translating knowledge across disciplines, institutions, borders, and health systems takes sustained, organized effort. It requires exactly the kind of infrastructure — the networks, the forums, the consensus processes, the educational programs, and the policy relationships — that The International Association of Gerontology and Geriatrics has spent more than seven decades building.
In the years ahead, the pace of discovery in aging science will only accelerate. Advances in genomics, digital biomarkers, artificial intelligence, and precision medicine will generate a new wave of findings with transformative potential for older patients. Whether that potential is realized will depend, in large part, on how quickly and effectively the field can move knowledge from where it is produced to where it is needed.
IAGG’s
mission is to ensure that the answer to that question keeps improving. For the older adults who stand to benefit, and for the clinicians working to serve them, that mission could not be more important.